HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schmidt, L. H. Search for Related Content PubMed PubMed Citation Articles by Schmidt, L. H.

Plasmodium Falciparum and Plasmodium Vivax Infections in the Owl Monkey (Aotus Trivirgatus)

III. Methods Employed in the Search for New Blood Schizonticidal Drugs^*

This report describes, illustrates, and validates the major features of a procedure designed to provide primary assessments of the activities of potential antimalarial drugs against infections with chloroquine-resistant or pyrimethamine-resistant strains of Plasmodium falciparum in owl monkeys of Colombian origin. Studies with 14 specially selected compounds have shown that the test method has the capacity to identify and quantify diverse levels of therapeutic efficacy among agents that differ widely in chemical structure. Extended studies with two of the above compounds indicate that such assessments have an acceptable level of reproducibility. Experiments with two other agents, structurally different from those in the selected group, have shown that the impacts of pyrimethamine resistance (or chloroquine resistance) on the activity of a compound can be readily identified during routine application of the test procedure, as can emergence of parasites resistant to the test agent. The above body of information can usually be acquired in infections with two strains of P. falciparum, one chloroquine-resistant, the other pyrimethamine-resistant, with commitments of no more than 1.5 g of test compound and 12 owl monkeys. These modest requirements have made it possible to utilize human plasmodial infections in the owl monkey in the search for new blood schizonticidal drugs more broadly effective than those currently available.

Accepted for publication January 7, 1978.

^* The experimental components of this report were supported by Contract DADA 17-69-C-9104 between the U.S. Army Medical Research and Development Command and the Southern Research Institute. Manuscript preparation was supported in part by the latter contract and in part by the Southern Research Institute. This is contribution number 1487 from the Army Research Program on Malaria.

Address reprint requests to: Dr. L. H. Schmidt, Kettering-Meyer Laboratory, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, Alabama 35205.